O1385
Ozagrel hydrochloride hydrate
≥98% (HPLC), solid
别名:
(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C13H12N2O2 · HCl · xH2O
化学文摘社编号:
分子量:
264.71 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Storage condition:
desiccated
Quality Segment
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
solubility
H2O: soluble
storage temp.
room temp
SMILES string
O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1
InChI
1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
InChI key
OWIZTYOMGVTSDP-TXOOBNKBSA-N
Application
Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:
- in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
- to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
- to test its effect on arteriolar vasoconstriction in hyperglycemic mice
Biochem/physiol Actions
Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.
Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)